Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agilent Acquires BIOCIUS Life Sciences

Published: Thursday, March 03, 2011
Last Updated: Thursday, March 03, 2011
Bookmark and Share
Agilent Technologies Inc. announces that it has acquired BIOCIUS Life Sciences, Inc., developer of the unique RapidFire™ high-throughput mass spectrometry drug-screening platform for the pharmaceutical and biopharmaceutical markets.

BIOCIUS' RapidFire drug-screening technology has successfully screened millions of compounds, providing results 10 to 100 times faster than traditional screening methods. Using high-throughput mass spectrometry and innovative microfluidics, the RapidFire system enables researchers to gain a fuller understanding of a drug's biochemical properties, including potential liabilities in drug interactions.

"BIOCIUS' unique RapidFire technology gives customers an unsurpassed ability to increase the effectiveness and reduce the cost of drug discovery and compound identification," said Gustavo Salem, vice president of Agilent's Biological Systems Division within the company's Life Sciences Group. "With this technology and the team that developed it now part of Agilent, we can expand our reach in the pharmaceutical and clinical mass spec markets."

"RapidFire instrumentation and research services are highly valued by leading drug discovery researchers around the globe," said Jeffrey Leathe, former chairman and chief executive officer of BIOCIUS. "As we continued to leverage those relationships and our experience into current and new markets, the natural evolution of the company was to partner with a world-class organization to accelerate our application development and further market penetration. Agilent's breadth of global resources and market strategy are the best fit for BIOCIUS to drive RapidFire into new markets going forward."

Based in Wakefield, Mass., privately held BIOCIUS was formed in 2009 as a spinoff from BioTrove Inc. Named from the Greek word "bio" (life) and the Latin word "ocius" (faster), BIOCIUS provided products and services committed to speed and accuracy across a range of applications, including drug discovery and ADME. Thirteen of the top 14 biopharmaceutical companies use products from BIOCIUS. The company employed about 25 people, who have now joined Agilent.

BIOCIUS' ultra high-speed automated valving, solid-phase extraction, and data-processing systems, when coupled with triple quadrupole or TOF/QTOF mass spectrometers, provide extremely high sample throughput for the biopharmaceutical market.

The company's products include the Rapid Fire 200, RapidFire 300 and RapidFire 360 high-throughput mass spectrometry systems. Agilent and BIOCIUS jointly announced the introduction of the RapidFire 360 in May 2010 at the annual American Society for Mass Spectrometry Conference.

The RapidFire 360 is designed for high-throughput screening of in vitro ADME assays. Combining the accurate mass capabilities of Agilent's time-of-flight mass spectrometers and the unprecedented sample processing speed of RapidFire technology, the instrument has revolutionized in vitro ADME analysis by eliminating the method development bottleneck in drug discovery.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Collaborate with A*STAR’s Bioprocessing Technology Institute
Collaboration addresses a critical need in the biopharmaceutical industry.
Tuesday, July 14, 2015
Agilent Supports Inaugural Singapore-South Korea Symposium on Glycomics
Event follows collaboration to develop tools for analysis of biologics, vaccines.
Saturday, February 15, 2014
Agilent Reports Fourth-Quarter Results
Agilent Technologies reported orders up 4 percent over one year ago to $1.83 billion with revenues of $1.72 billion, down 3 percent compared with one year ago.
Monday, November 18, 2013
Agilent and Seoul National University Hospital Collaborate
The strategic collaboration will focus on the development and verification of various biomarkers for the development of drugs, including narcotics, immune-suppressants and biomarkers.
Friday, October 18, 2013
Agilent Technologies and SomaLogic Enter Agreement
The agreement will expand access to SomaLogic's unbiased protein biomarker discovery platform.
Tuesday, August 13, 2013
Agilent Technologies Announces Winner of Fifth Annual Early Career Professor Award
Assistant Professor at Northwestern Recognized for Cancer Diagnostics Research.
Friday, May 10, 2013
Agilent Technologies and Chungnam National University Announce Glycomics Research Initiatives
The collaboration hopes to develop biomarkers and new therapeutic antibodies to combat diseases such as cancer.
Tuesday, April 02, 2013
Agilent and Applied Proteomics Will Collaborate
Collaboration to maximize capabilities of highly multiplexed protein assays.
Friday, March 08, 2013
Agilent Collaborating with Florida International University
Collaboration to further advance the identification and characterization of designer drugs.
Tuesday, February 26, 2013
Agilent Technologies and Ameritox Form Collaboration
Agilent Technologies Inc. and AmeritoxSM announced that they have formed a research collaboration that could accelerate analysis in the field of medication monitoring.
Tuesday, February 12, 2013
Agilent Technologies Collaborates with Gachon University
World-leading research laboratory at Gachon will have access to the latest technologies from Agilent and a beta test site for new solutions.
Monday, July 23, 2012
Agilent Technologies Reports Second-Quarter 2012 Results
Third-quarter fiscal year 2012 revenue guidance of $1.77 billion - $1.79 billion and non-GAAP earnings guidance of $0.82 - $0.84 per share.
Wednesday, May 16, 2012
Agilent and Integrated Diagnostics Enter Strategic Partnership
The partnership will develop protein-based assays for early disease detection.
Wednesday, January 11, 2012
Agilent Technologies and Chungnam National University Collaborate to Further Glycomics Research
The university aims to identify and develop biomarkers for diseases.
Friday, August 26, 2011
Agilent Technologies and A*STAR’s ETC Launch All-in-One Drug-Screening Platform at Singapore Screening Centre
Agilent to provide a full spectrum of automation technologies to biomedical researchers, enabling highly efficient drug screening in one location.
Tuesday, August 02, 2011
Scientific News
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
FNIH Launches Project to Evaluate Biomarkers in Cancer Patients
Company has announced that it has launched a new project to evaluate the effectiveness of liquid biopsies as biomarkers in colorectal cancer patients.
Drugs that May Combat Deadly Antibiotic-Resistant Bacteria Uncovered
Study identifies 79 compounds that inhibit carbapenem-resistant Enterobacteriaceae (CRE).
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!